In the meantime, patients who are prescribed a GLP-1 medication for obesity or diabetes and who also drink may experience reduced cravings as a secondary benefit
Keller, J., Beglinger, C., Holst, J
Initial stages of the project were supported by Diabetes UK RD Lawrence Fellowship (RR and QZ), a Novo Nordisk University of Oxford postdoctoral fellowship (CG) and a project grant from the Rosetrees Trust (PR)
The differential exists because PBMs negotiate chain rates against the threat of in-house retail pharmacy competition (since CVS and OptumRx both own pharmacies), while independent PSAOs have no comparable countervailing leverage
The complementary mechanisms of action can provide additive cardiovascular risk reduction
Khatua B, El-Kurdi B, Singh VP